Type 2 diabetes mellitus (T2DM) and obesity are closely linked diseases that are increasing in prevalence in the United States as well as worldwide and have reached pandemic proportions (Artasensi et al, 2023). Both conditions have serious impacts on multiple body systems and are associated with increased mortality and cardiovascular risk, and both share genetic and environmental factors in their pathogenesis (Grant et al, 2021; Ruze et al, 2023). The development of drugs that treat both these conditions holds great promise for improving the health of individuals with chronic cardiometabolic disorders (Drucker, 2024). This activity will provide an overview of glucose-lowering medications’ effect on body weight, emerging data on novel anti-obesity medications, and the therapeutic potential of agents for the simultaneous management of obesity and type 2 diabetes mellitus.
- Provider:i3 Health
- Activity Link: https://i3health.com
- Start Date: 2024-10-24 05:00:00
- End Date: 2024-10-24 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Endocrinology, Diabetes, and Metabolism, Internal Medicine